Ad is loading...
MDGL
Price
$347.45
Change
+$18.21 (+5.53%)
Updated
Nov 22 closing price
95 days until earnings call
NNVC
Price
$1.34
Change
+$0.06 (+4.69%)
Updated
Nov 22 closing price
4 days until earnings call
Ad is loading...

MDGL vs NNVC

Header iconMDGL vs NNVC Comparison
Open Charts MDGL vs NNVCBanner chart's image
Madrigal Pharmaceuticals
Price$347.45
Change+$18.21 (+5.53%)
Volume$538.34K
CapitalizationN/A
NanoViricides
Price$1.34
Change+$0.06 (+4.69%)
Volume$133.74K
CapitalizationN/A
MDGL vs NNVC Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NNVC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
MDGL vs. NNVC commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and NNVC is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (MDGL: $347.45 vs. NNVC: $1.34)
Brand notoriety: MDGL and NNVC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 119% vs. NNVC: 83%
Market capitalization -- MDGL: $7.58B vs. NNVC: $19.22M
MDGL [@Biotechnology] is valued at $7.58B. NNVC’s [@Biotechnology] market capitalization is $19.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileNNVC’s FA Score has 1 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • NNVC’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than NNVC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 5 TA indicator(s) are bullish while NNVC’s TA Score has 4 bullish TA indicator(s).

  • MDGL’s TA Score: 5 bullish, 6 bearish.
  • NNVC’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both MDGL and NNVC are a bad buy in the short-term.

Price Growth

MDGL (@Biotechnology) experienced а +20.40% price change this week, while NNVC (@Biotechnology) price change was +8.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

MDGL is expected to report earnings on Feb 26, 2025.

NNVC is expected to report earnings on Feb 12, 2025.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.58B) has a higher market cap than NNVC($19.2M). MDGL YTD gains are higher at: 50.164 vs. NNVC (31.373). NNVC has higher annual earnings (EBITDA): -8.67M vs. MDGL (-502.65M). MDGL has more cash in the bank: 999M vs. NNVC (3.87M). NNVC has less debt than MDGL: NNVC (1.5M) vs MDGL (119M). MDGL has higher revenues than NNVC: MDGL (76.8M) vs NNVC (0).
MDGLNNVCMDGL / NNVC
Capitalization7.58B19.2M39,469%
EBITDA-502.65M-8.67M5,795%
Gain YTD50.16431.373160%
P/E RatioN/AN/A-
Revenue76.8M0-
Total Cash999M3.87M25,841%
Total Debt119M1.5M7,933%
FUNDAMENTALS RATINGS
MDGL vs NNVC: Fundamental Ratings
MDGL
NNVC
OUTLOOK RATING
1..100
2470
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
24100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3665
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
11n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NNVC's Valuation (28) in the Biotechnology industry is somewhat better than the same rating for MDGL (71) in the Pharmaceuticals Other industry. This means that NNVC’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (24) in the Pharmaceuticals Other industry is significantly better than the same rating for NNVC (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than NNVC’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as NNVC (98) in the Biotechnology industry. This means that MDGL’s stock grew similarly to NNVC’s over the last 12 months.

MDGL's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as NNVC (65) in the Biotechnology industry. This means that MDGL’s stock grew similarly to NNVC’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as NNVC (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to NNVC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLNNVC
RSI
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
82%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NNVC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BSBR4.530.16
+3.66%
Banco Santander (Brasil) SA
OBK35.020.77
+2.25%
Origin Bancorp
IRTC73.990.09
+0.12%
iRhythm Technologies
AMS3.14-0.02
-0.63%
American Shared Hospital Services
GNFT4.20-0.04
-0.94%
Genfit SA

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+5.53%
KANT - MDGL
62%
Loosely correlated
-10.86%
VXRT - MDGL
61%
Loosely correlated
+0.12%
ALXO - MDGL
56%
Loosely correlated
+9.30%
REPL - MDGL
55%
Loosely correlated
+35.11%
ZNTL - MDGL
51%
Loosely correlated
+1.57%
More

NNVC and

Correlation & Price change

A.I.dvisor indicates that over the last year, NNVC has been loosely correlated with MDGL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NNVC jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NNVC
1D Price
Change %
NNVC100%
+4.69%
MDGL - NNVC
34%
Loosely correlated
+5.53%
CYTK - NNVC
31%
Poorly correlated
+3.00%
IFRX - NNVC
30%
Poorly correlated
+0.97%
AXON - NNVC
29%
Poorly correlated
+0.90%
ORMP - NNVC
28%
Poorly correlated
+1.30%
More